Abstract | BACKGROUND/AIMS: METHODOLOGY: RESULTS: Total 2-year recurrence rate was 8.7%. When these 38 patients were divided into two groups according to preoperative lamivudine therapy duration: group 1 (n = 11) 4 weeks or more and group 2 (n = 27) less than 4 weeks, recurrences were detected in 3 (27.2%) and 4 (14.8%) patients in groups 1 and 2, respectively, i.e. a similar recurrence rate in both groups (p = 0.390). Moreover, in a subgroup of 20 patients who received preoperative lamivudine therapy for less than one week, only one (5%) experienced HBV recurrence. CONCLUSIONS: Our findings indicate that postoperative combination prophylaxis is effective and that preoperative lamivudine therapy is unlikely to be obligatory despite a positive preoperative serum HBV DNA status.
|
Authors | Hae Won Lee, Kyung-Suk Suh, Nam-Joon Yi, Sung Hoon Yang, Eung-Ho Cho, Jai Young Cho, Choon Hyuck Kwon, Yong Beom Cho, Kuhn Uk Lee |
Journal | Hepato-gastroenterology
(Hepatogastroenterology)
Vol. 54
Issue 78
Pg. 1783-7
(Sep 2007)
ISSN: 0172-6390 [Print] Greece |
PMID | 18019718
(Publication Type: Journal Article)
|
Chemical References |
- DNA, Viral
- Immunoglobulins
- Immunosuppressive Agents
- Lamivudine
|
Topics |
- Adult
- DNA, Viral
(blood, metabolism)
- Female
- Hepatitis B
(drug therapy, immunology, virology)
- Humans
- Immunoglobulins
(chemistry)
- Immunosuppressive Agents
- Lamivudine
(therapeutic use)
- Liver Transplantation
(methods)
- Male
- Middle Aged
- Models, Statistical
- Recurrence
- Treatment Outcome
|